A Study to Assess the Use of Artificial Intellignce to Predict Eye Treatment Changes in Adult Participants With Diabetic Macular Edema

Starting soon

Conditions studied: Diabetic Macular Edema

In brief

This study is to assess the use of Artificial intellignce (AI) to predict eye treatment changes in adult participants with diabetic macular edema (DME).

Key facts

Study ID

NCT07604545

Run by

AbbVie

People needed

554

Starts

2026-05-30

Expected to finish

2027-03-01

Last updated by the study team

2026-05-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Previously untreated Diabetic macular edema (DME) Participants.
• Baseline macular edema ≥350 microns confirmed on Spectralis Standard deviation (SD)-Optical coherence tomography (OCT) or equivalent.
• Baseline Best corrected visual acuity (BCVA) between 23 and 78 Early treatment diabetic retinopathy study (ETDRS) letters (between 20/32 and 20/230 Snellen).

You may not qualify if…

• History of eyes with previous intravitreal or laser treatment for DME.
• History of eyes with previous intraocular or periocular corticosteroid for DME.
• History eyes with other macular disease, causing visual reduction or disturbance.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.